Your browser version may not work well with NCBI's Web applications. More information here...
1: Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3.Click here to read Links

Recent updates on the role of chemotherapy in pancreatic cancer.

Burris HA 3rd.

The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, USA. hburris@tnonc.com

Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of gemcitabine with erlotinib was associated with a significant prolongation of survival. Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated.

PMID: 16143160 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Erlotinib (Tarceva®) Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.
    » read more ...